Related references
Note: Only part of the references are listed.Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Deborah L. White et al.
BLOOD (2007)
How I treat chronic myeloid leukemia in the imatinib era
John M. Goldman
BLOOD (2007)
Imatinib disposition and ABCB1 (MDR1, p-glycoprotein) genotype
H. Gurney et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph plus CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon
M. Breccia et al.
LEUKEMIA RESEARCH (2006)
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E. Jabbour et al.
LEUKEMIA (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study
H Schmidli et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Genetics of the variable expression of CYP3A in humans
L Wojnowski
THERAPEUTIC DRUG MONITORING (2004)
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients
B Peng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate
T Illmer et al.
LEUKEMIA (2004)
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
AE Bolton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Effect of St John's wort on imatinib mesylate pharmacokinetics
RF Frye et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
To the editor: Discontinuation of imatinib therapy after achieving a molecular response
J Cortes et al.
BLOOD (2004)
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas et al.
BLOOD (2004)
The influence of St. John's Wort on the pharmacokinetics and protein binding of imatinib mesylate
P Smith
PHARMACOTHERAPY (2004)
Imatinib therapy in chronic myeloid leukemia
LC Crossman et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
S Branford et al.
BLOOD (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
